Semisyngeneic hybrid resistance to murine teratocarcinoma cells

G A Bishop1, W F Dove

  • 1McArdle Laboratory for Cancer Research, The University of Wisconsin. Madison, Wisconsin 53706, USA.

Immunogenetics
|March 31, 2012
PubMed

Insights

Hybrid mice show increased resistance to embryonal carcinoma cell lines. This enhanced immunity, observed in F1 hybrids, suggests a significant immunological basis for tumor rejection, independent of the H-2 complex.

Area of Science:

  • Immunology
  • Developmental Biology
  • Cancer Research

Background:

  • Murine embryonal carcinoma (EC) cells are used as models for early development and cancer.
  • Understanding resistance mechanisms to EC cells is crucial for cancer immunotherapy.
  • Previous studies suggested genetic factors influence tumor rejection.

Purpose of the Study:

  • To investigate the resistance of F1 hybrid mice to established murine embryonal carcinoma cell lines.
  • To determine if hybrid resistance is dependent on the H-2 histocompatibility complex.
  • To elucidate the immunological basis of hybrid resistance to EC cells.

Main Methods:

  • Generation of F1 hybrid mice by crossing strain 129/J with allogeneic mouse strains.
  • In vivo studies assessing tumor growth and resistance of hybrid mice against PCC3 (multipotent) and F9 (nullipotent) EC lines.
  • Analysis of H-2 complex compatibility in resistant hybrid strains.

Main Results:

  • Three out of four F1 hybrid strains exhibited significantly enhanced resistance to the PCC3 EC line compared to the 129/J parent strain.
  • All tested F1 hybrid strains demonstrated significantly higher resistance to the F9 EC line than the syngeneic 129/J strain.
  • Hybrid resistance was observed even in the absence of a hybrid H-2 complex.

Conclusions:

  • F1 hybrid mice possess a potent, genetically controlled resistance to murine embryonal carcinoma cells.
  • This hybrid resistance is mediated by immunological mechanisms and is not solely dependent on the H-2 histocompatibility complex.
  • The findings provide insights into non-MHC-mediated tumor rejection mechanisms.